OBJECTIVES:
Primary Objectives
1.To evaluate the safety and feasibility of the sequential use of a DNA methyltransferase
(DNMT) inhibitor (decitabine) with a targeted biological agent against EGFR (panitumumab) for
KRAS wild type tumors in the second or third line treatment of advanced metastatic colorectal
cancer.
Secondary Objectives
1. To examine re-expression or a reduction in promoter methylation in genes involved in
tumor suppressor pathways known to be important in colorectal cancer (CRC) or involved
in EGFR signaling pathway.
2. Evaluate overall response (OR = CR +PR) according to RECIST criteria at 2, 4, and 6
cycles. Progression free survival, measured as the first evidence of tumor growth from
the start of treatment will also be assessed.
3. Measure CEA levels at the beginning of each cycle to examine if they correlate with
treatment response or disease progression.